Video

Dr. Ravi on unmet needs in PSMA-targeted paradigm

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Praful Ravi, MB, BChir, MRCP, discusses remaining needs and next steps with PSMA-targeted agents in prostate cancer.Ravi is a medical oncologisxt at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
      Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      PSMA PET and treatment intensification in mHSPC
      Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
      Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
      Amar Kishan, MD, on implications of MIRAGE trial data
      Amar Kishan, MD, on implications of MIRAGE trial data
      Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
      Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
      Amar Kishan, MD, outlines the rationale for the MIRAGE trial
      Amar Kishan, MD, outlines the rationale for the MIRAGE trial
      Michael Cookson, MD, on potential future applications of PSMA-PET
      Michael Cookson, MD, on potential future applications of PSMA-PET
      Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
      Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
      Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
      Related Content
      3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      July 18th 2025

      Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

      Hannah Clarke
      The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
      June 22nd 2023

      Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

      Urology Times staff
      "We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
      Trial launches of diagnostic agent for clear cell renal cell carcinoma
      June 23rd 2025

      Trial launches of diagnostic agent for clear cell renal cell carcinoma

      Hannah Clarke
      Arm D of the trial is assessing the performance of [68Ga]Ga-DPI-4452 in detecting ccRCC in patients with an indeterminate renal mass.
      FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting
      June 23rd 2025

      FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting

      Hannah Clarke Jason M. Broderick
      The label expansion follows the FDA approval of an expanded label for 177Lu-PSMA-617 for use in patients with mCRPC after ARPI therapy and before chemotherapy.
      3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      June 13th 2025

      64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence

      Hannah Clarke
      The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin.
      PSMA-PET imaging product, Gozellix, launches on US market
      June 11th 2025

      PSMA-PET imaging product, Gozellix, launches on US market

      Hannah Clarke
      Gozellix was approved by the FDA in March 2025.
      © 2025 MJH Life Sciences

      All rights reserved.